ACELYRIN is based in Los Angeles. It has raised $758M in total funding. Latest round: Series C.
ACELYRIN funding overview
ACELYRIN is based in Los Angeles. ACELYRIN has raised $758M in total disclosed funding. That places its disclosed total in the $250M–$1B range. Its most recent disclosed round is a Series C announced in September 2022. The round record for ACELYRIN runs through 2022; nothing later has been disclosed. Investors on record include Access Biotechnology, Atlas Venture, Contrary Capital, VenBio Partners, Westlake Village BioPartners, OrbiMed and 5 others. 11 distinct backers are named across the disclosed rounds.
ACELYRIN has raised $758M in total disclosed funding across the rounds on record.
Who has invested in ACELYRIN?
Access Biotechnology, Atlas Venture, Contrary Capital, VenBio Partners, Westlake Village BioPartners, OrbiMed are named among the investors backing ACELYRIN.
What was the latest ACELYRIN funding round?
The most recent disclosed round is a Series C, announced in September 2022.
Where is ACELYRIN based?
ACELYRIN is based in Los Angeles.
When did ACELYRIN last raise?
The last disclosed ACELYRIN round closed in September 2022 at Series C.
Totals shown for ACELYRIN aggregate every disclosed round on file. To see how that compares, browse the companies in Los Angeles and the investors behind them below.
